Storia in 7 fonti

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo3 mesi fa

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to…

originale

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Confronto fonti

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to…

Timeline cronologica

Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026

Akeso, Summit drug extends survival in closely watched lung cancer trial

Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo in Advanced NSCLC

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

Akeso, Summit drug extends survival in closely watched lung cancer trial

Akeso lung cancer drug cuts death risk 34% in landmark trial

Newly developed drug helps extend the lives of lung cancer patients in trial

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

New drug a ‘promising step forward’ for hard-to-treat lung cancer

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in…

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy…

Newly developed drug helps extend the lives of lung cancer patients in trial

Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo in Advanced NSCLC

Akeso lung cancer drug cuts death risk 34% in landmark trial